KAD-1229
Phase 3Completed 0 watching 0 views this week๐ Rising
76
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes
Conditions
Type 2 Diabetes
Trial Timeline
โ โ Nov 1, 2012
NCT ID
NCT01333592About KAD-1229
KAD-1229 is a phase 3 stage product being developed by Kissei Pharmaceutical for Type 2 Diabetes. The current trial status is completed. This product is registered under clinical trial identifier NCT01333592. Target conditions include Type 2 Diabetes.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01333592 | Phase 3 | Completed |
Competing Products
20 competing products in Type 2 Diabetes